However, despite a moderate survival advantage when combined with a platinum-based agent or radiation therapy [13,14], cetuximab remains clinically limited in HNSCC due to intrinsic and acquired mechanisms of resistance to the EGFR blockade [15]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.